Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
908 Devices Inc. develops purpose-built handheld chemical analysis devices for point-of-need use in health, safety and defense technology applications. Its news centers on Mass Spec and FTIR product activity, installed-device growth, recurring revenue, and applications such as narcotics identification, toxic exposure screening and security-threat analysis.
Company updates also cover acquisitions and portfolio expansion, including the completed purchase of NIRLAB AG and its AI-powered, cloud-connected near-infrared spectroscopy platform for narcotics screening. Other recurring items include quarterly financial results, revenue outlooks, executive and strategy appointments, funded partnership revenue, and investor conference participation.
908 Devices (NASDAQ:MASS) has been selected by the U.S. Border Patrol to deploy over 60 units of its MX908 handheld mass spectrometry device across 20 locations in the U.S. and Caribbean. This device is pivotal for trace drug detection, aiding in the prevention of drug smuggling. The announcement comes amid rising drug overdose deaths in the U.S., which increased nearly 17% from May 2019 to 2020. The MX908 can identify over 2,000 fentanyl analogs, enhancing the capabilities of law enforcement agencies in combating the opioid crisis.
908 Devices reported a strong 2020, with revenue increasing 50% year-over-year to $26.9 million. The gross margin improved to 55% from 45% in 2019. Despite a 32% revenue decline in Q4 2020, attributed to decreased license revenue, the company projects full-year 2021 revenue between $38 million to $40 million, reflecting a 41% to 49% growth. The company also strengthened its leadership team and secured a $25 million order from the U.S. Army, enhancing its business outlook.
908 Devices has secured a multi-year purchase order worth $25 million from the U.S. Army for over 350 MX908 trace-level detection devices. These devices will be incorporated into the Army's Explosive Ordnance Disposal (EOD) program over the next two years. The MX908's high-pressure mass spectrometry technology allows for rapid detection and identification of chemical threats, priority drugs, and trace explosives at the point of need. This commitment extends through 2025, showcasing the demand for advanced detection technology in military operations.
908 Devices (NASDAQ: MASS) announced the appointment of Jeff George and Fenel Eloi to its Board of Directors. Jeff brings over 20 years of experience in healthcare leadership, having served as CEO for major divisions at Novartis. Fenel, a seasoned life science executive, previously served as CFO and COO at Cell Signaling Technology. Their appointments aim to strengthen the company’s growth strategies in mass spectrometry technology. Prof. J. Michael Ramsey and Sharon Kedar will step down from the board at the upcoming Annual Meeting in June.
908 Devices Inc. (Nasdaq: MASS) will report its financial results for Q4 and the full year of 2020 on March 30, 2021, before market open. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET. The webcast can be accessed on the company’s website, with an archive available within 24 hours. 908 Devices specializes in handheld and desktop mass spectrometry devices for various critical applications in life sciences, bioprocessing, and forensics, focusing on providing quick, actionable insights.
908 Devices, listed on Nasdaq as MASS, announced its participation in two upcoming virtual investor conferences. The 10th Annual SVB Leerink Global Healthcare Conference will feature a fireside chat on February 26 at 12:40 PM PT, while the Cowen 41st Annual Health Care Conference will take place on March 3 at 10:20 AM PT. Interested investors can access live and archived webcasts on the company’s website. 908 Devices specializes in handheld and desktop mass spectrometry solutions, focusing on critical applications in life sciences, bioprocessing, and forensics.
908 Devices, a leader in handheld and desktop mass spectrometry, has successfully completed its upsized initial public offering (IPO) of 7,475,000 shares at a price of $20.00 per share. The offering included the underwriters’ full option to purchase an additional 975,000 shares. The shares commenced trading on the Nasdaq Global Market under the ticker symbol MASS on December 18, 2020. The proceeds from the offering are intended to enhance the company’s product development and market penetration.
908 Devices announced the pricing of its upsized initial public offering (IPO) of 6,500,000 common stock shares at $20.00 each, aiming to raise $130 million gross proceeds. The underwriters have a 30-day option to purchase an additional 975,000 shares. Trading is set to begin on Nasdaq under the symbol 'MASS' on December 18, 2020, with the offering expected to close on December 22, 2020. Cowen and SVB Leerink are the lead book-running managers for the offering. The company specializes in handheld and desktop mass spectrometry devices for critical applications in various sectors.